

**CONCLUSION**

If the examiner has any questions concerning this application, he or she is requested to contact the undersigned.

Respectfully submitted,

Date 6/25/03

By 

FOLEY & LARDNER  
Washington Harbour  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007-5109  
Telephone: (202) 672-5475  
Facsimile: (202) 672-5399


Beth A. Burrous  
Attorney for Applicant  
Registration No. 35,087

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No. 19-0741 for any such fees; and applicant(s) hereby petition for any needed extension of time.

**Version with Markings to Show Changes Made**

14. (2X Amended) A method of [modulating abnormal cell proliferation, modulating the activity of] inhibiting VEGF, FGF, or PDGF stimulated cell proliferation in vein endothelial cells or smooth muscle cells [on cells *in vivo* or *in vitro* or modulating tyrosine kinase signal transduction,] comprising administering to a patient in need of such treatment a [pharmaceutically acceptable] composition comprising a therapeutically effective amount of [said] one or more compounds of formula I,

wherein said composition optionally includes one more pharmaceutically acceptable excipients in at least one of parenteral, oral, or topical formulation:



wherein,

R<sub>1</sub> is H or alkyl;

R<sub>2</sub> is O or S;

R<sub>3</sub> is H;

R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, and R<sub>7</sub> are each independently selected from the group consisting of hydrogen alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO<sub>2</sub>NRR', SO<sub>3</sub>R, SR, NO<sub>2</sub>, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R, CONRR', and (CH<sub>2</sub>)<sub>n</sub>ONRR';

A is selected from the group consisting of [a] 4,5,6,7-tetrahydroindole, [and a five-membered heteroaryl ring, wherein said five-membered ring is selected from the group consisting of] thiophene, pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, oxazole,

isoxazole, thiazole, isothiazole, 2-sulfonylfuran, 4-alkylfuran, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3,4-oxatriazole, 1,2,3,5-oxatriazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, 1,3,4-thiadaizole, 1,2,3,4-thiatriazole, 1,2,3,5-thiatriazole, and tetrazole, wherein said [five-membered ring and said tetrahydroindole are] group is optionally substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO<sub>2</sub>NRR', SO<sub>3</sub>R, SR, NO<sub>2</sub>, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R, CONRR', and (CH<sub>2</sub>)<sub>n</sub>ONRR';

n is 0-3;

R is selected from the group consisting of H, alkyl, and aryl; and

R' is selected from the group consisting of H, alkyl, and aryl, wherein said alkyl is optionally substituted with a six-membered heteroaliphatic ring, and wherein said six-membered ring is optionally substituted at one or more positions with substituents selected from the group consisting of alkyl, alkoxy, halogen, trihalomethyl, NO<sub>2</sub>, and (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R.